Nrf2 regulators
The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
1. A compound which is 3-(3-(((R)-4-ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable excipient.
3. A method of activating Nrf2 in a human in need thereof comprising administering to said human a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 1 .
4. A compound which is (R)-3-(3-(((R)-4-ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid or pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 4 and a pharmaceutically acceptable excipient.
6. A method of activating Nrf2 in a human in need thereof comprising administering to said human a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 4 .
7. A compound which is (S)-3-(3-(((R)-4-ethyl-1,1-dioxido-3,4-dihydro-2H-pyrido[2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl)-3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid or a pharmaceutically acceptable salt thereof.
8. A method of activating Nrf2 in a human in need thereof comprising administering to said human a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 7 .
9. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 7 and a pharmaceutically acceptable carrier or excipient.
10. A compound which is (S)-3-(3-(((R)-4-ethyl-1, 1-dioxide-3,4-dihyrdro-2H-pyrido [2,3-b][1,4,5]oxathiazepin-2-yl)methyl)-4-methylphenyl) -3-(1-ethyl-4-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoic acid.
11. A pharmaceutical composition comprising the compound according to claim 10 and a pharmaceutically acceptable excipient.
12. A method of activating Nrf2 in a human in need thererof comprising administering to said human a therapeutically effective amount of the compound according to claim 10 .